Enliven Therapeutics, Inc. (ELVN): Free Cash Flow
-$70.46M
Year ended 2025-12-31
-$67.04M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$70.46M | n/m | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | -$73.24M | n/m | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | -$61.42M | n/m | 2025-03-13, From 2023-01-01 |
| 2022-12-31 | -$32.69M | n/c | 2024-03-14, From 2022-01-01 |
| 2021-12-31 | -$46.78M | n/m | 2023-02-10, From 2021-01-01 |
| 2020-12-31 | -$37.42M | n/m | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | -$22.02M | n/a | 2021-03-05, From 2019-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | 2025-12-31 | -$70.46M | n/m |
| MapLight Therapeutics, Inc. (MPLT) | 2025-12-31 | -$138.61M | n/m |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | -$116.63M | n/m |
| Theravance Biopharma, Inc. (TBPH) | 2025-12-31 | $238.50M | n/m |
| Oruka Therapeutics, Inc. (ORKA) | 2025-12-31 | -$88.42M | n/a |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | -$110.44M | n/m |
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$43.98M | n/m |
| Biohaven Ltd. (BHVN) | 2025-12-31 | -$610.15M | n/m |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | 2025-12-31 | -$114.50M | n/m |
Compare ELVN, MPLT, RYTM, TBPH side by side · Screen every company in Pharmaceutical Preparations ↗